• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Teva Is Said to Pay $250 Million to End Nevada Colonoscopy Hepatitis Cases


Teva Pharmaceutical Industries Ltd. (TEVA)

will pay more than $250 million to settle more than 80 lawsuits alleging the drugmaker sold the anesthetic Propofol in a way that led colonoscopy patients to develop hepatitis C, people familiar with the accords said.

Teva, the world’s biggest maker of generic medicines, confirmed the settlement today without specifying how much it will pay. The company agreed last week to resolve claims by Las Vegas residents that it intentionally sold Propofol in vials large enough to be reused by doctors, the people said. They spoke on the condition they not be named because they aren’t authorized to speak publicly about the agreements.

Read the full story: http://hcp.lv/zYBngG

Source: Bloomberg

Related Videos
Related Content
© 2024 MJH Life Sciences
All rights reserved.